Navigation Links
Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Date:2/12/2008

S, net 817,828 793,037

DEFERRED TAX ASSETS, net 160,134 118,192

OTHER ASSETS 129,371 105,287

$3,506,269 $3,045,497

CURRENT LIABILITIES:

Current portion of long-term debt $1,237,169 $1,023,312

Accounts payable 91,437 90,586

Accrued expenses 677,184 263,478

Total current liabilities 2,005,790 1,377,376

LONG-TERM DEBT 3,788 224,992

DEFERRED TAX LIABILITIES, net 56,540 72,491

OTHER LIABILITIES 138,084 61,178

Total liabilities 2,204,202 1,736,037

STOCKHOLDERS' EQUITY:

Common stock, $0.01 par value 700 678

Additional paid-in capital 1,934,965 1,780,749

Treasury stock, at cost (158,173) (151,068)

Accumulated deficit (624,128) (425,256)

Accumulated other comprehensive income 148,703 104,357

Total stockholders' equity 1,302,067 1,309,460

$3,506,269 $3,045,497

Certain reclassifications of prior year amounts have been made to conform

to the current year presentation. The NUVIGIL(R) (armodafinil) [C-IV]

inventory balance of $89.1 million as of December 31, 2006 has been

reclassified from inventory to other assets, as we do not presently intend

to launch NUVIGIL commercially until around 2010.

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATE
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Marshall, MN (PRWEB) , ... July 31, 2015 , ... ... Ralco Enrichment Center at the Lyon County Fair to be held August 5-9 in ... more about where their meals come from and how agriculture impacts their daily lives. ...
(Date:7/30/2015)... July 30, 2015 According to ... (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, ... Preclinical, Clinical Trial), by End Users - Global Forecast ... expected to reach USD 2,107.99 million by 2020 from ... 15.29%. Browse more than ...
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... received,additional sales orders in excess of one half million ... recent cross-country sales,initiative. These purchase orders are currently resulting ... achieving break-even status,by the end of January, 2008, or ... About Signalife: Signalife, Inc. is an award-winning ...
... 10 DermTech International, Inc.,a biotechnology company ... of melanoma and other diseases, today appointed ... Board. Dr. Quackenbush is a,Professor of Biostatistics ... and Professor of Computational Biology and Bioinformatics,at ...
... Oct. 9 For Hispanic-Americans without health,insurance, it ... as doctor,visits and prescription medicines. However, help is ... prescribed by their doctors. Listen to this ... http://media.medialink.com/WebNR.aspx?story=33947 Registered journalists can access video, ...
Cached Biology Technology:Signalife Continues to Procure Purchase Orders, Revenues 2DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Company's Scientific Advisory Board 2
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market ... Report: The Convergence of Commerce and Privacy" forecasts ... mobile biometric apps will be downloaded to smart ... The mobile biometrics market is projected to generate ... revenue during the seven-year forecast period.    ...
(Date:7/13/2015)... 13, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND ... and secure method to make payments.  With this ... introduced with its groundbreaking voice-direct payment patent application, ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... of Copenhagen have agreed to set up a ... resources can benefit the country. Greenland,s premier, Kuupik ... support the initiative. The committee will examine ... how they can create value for Greenland through, ...
... A South Dakota School of Mines & Technology ... species of herbivorous dinosaur and published the first fossil ... Research by Clint Boyd, Ph.D., provides the first definitive ... of choice for the crocodyliform, a now extinct relative ...
... of hundreds of thousands of individuals (known as Genome-wide ... regions in the genome to the risk of developing ... (EMBL) and the University of Heidelberg, through the joint ... one step further by pinpointing the exact genes that ...
Cached Biology News:Experts to calculate potential of Greenlandic mineral wealth 2Research unearths new dinosaur species 2Research unearths new dinosaur species 3Zeroing in on heart disease 2
...
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
...
... interface for data capture, recording, manipulation, ... from paper to this powerful solution ... an integrated LIMS, notary service, customer ... functions allow LABTrack to achieve in ...
Biology Products: